Biovica International AB Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : So first here, you mentioned in the report that you received orders from pharma companies using DiviTum when developing new cancer drugs. Is this an area you expect that will increase significantly once the FDA clearance is in place potentially here? Or are these European customers? How should we think about that opportunity going forward?

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Yes. Yes. Sure, sure. And you spoke a little bit about it, but expanding DiviTum's indications or intended use from monitoring to prognostic. How long do you believe that process will take? And is that more competitive setting or more commercially challenging setting would be interesting to hear as well. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 18, 2021 / 9:00AM, BIOVICb.ST - Q3 2021 Biovica International AB Earnings Call

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Sure. Sure. And you spoke a little bit about it regarding potential for interventional study here with the DiviTum. Can you communicate on the time line when you can expect such a study to be started? And can you also communicate potentially how long such a study would take to perform in your estimates currently?

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Yes, sure. And just a final question from my side. Could you please clarify the commercialization path and perhaps a status update between the